- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
UGT2A3 Antibody (Center)Peptide Affinity Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP17728c | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
| AP17728c-ev20 | 20 ug 100 ul | In Stock | $ 95.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
UGT2A3 Antibody (Center) - Product info | |
| Application | WB
|
| Primary Accession | Q6UWM9 |
| Other Accession | NP_079019.3 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 60254 Da |
UGT2A3 Antibody (Center) - Additional info | |
| Gene ID 79799 | |
| Other Names UGT2A3; UDP-glucuronosyltransferase 2A3 | |
| Target/Specificity This UGT2A3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 323-353 amino acids from the Central region of human UGT2A3. | |
| Dilution WB~~1:100~500WB~~1:1000 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions UGT2A3 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures. | |
UGT2A3 Antibody (Center) - Protein Information | |
| Name UGT2A3 | |
| Function UDP-glucuronosyltransferases catalyze phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase water solubility and enhance excretion. They are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds (By similarity) | |
| Cellular Location Membrane; Single-pass type I membrane protein (Potential) | |
UGT2A3 Antibody (Center) - Related products
UGT2A3 Antibody (Center) - Application data
-
UGT2A3 Antibody (Center) (Cat. #AP17728c) western blot analysis in NCI-H460 cell line lysates (35ug/lane).This demonstrates the UGT2A3 antibody detected the UGT2A3 protein (arrow).
UGT2A3 Antibody (Center) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
UDP-glucuronosyltransferases catalyze phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase water solubility and enhance excretion. They are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds (By similarity).
REFERENCES
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) : Sneitz, N., et al. Pharmacogenet. Genomics (2009) In press : Court, M.H., et al. Mol. Pharmacol. 74(3):744-754(2008) Clark, H.F., et al. Genome Res. 13(10):2265-2270(2003)
